Psychosocial Outcomes in Insulin

The Influence of Real-Time Continuous Glucose Monitoring on Psychosocial Outcomes in Insulin-Using Type 2 Diabetes

Authors: Emily C Soriano, William H Polonsky

Abstract

Background: To examine the impact of real-time continuous glucose monitoring (rtCGM) on psychosocial outcomes in adults with insulin-using type 2 diabetes (T2D).

Methods: A total of 174 insulin-using adults with T2D completed questionnaires assessing diabetes distress, hypoglycemic confidence, hypoglycemic fear, device-related emotional burden, and device-related trust before and after a six-month trial of rtCGM. Hemoglobin A1c (HbA1c) was assessed at the same time points; impaired hypoglycemic awareness (IAH) was assessed at baseline. Change in psychosocial outcomes was examined with t tests, then modeled as a function of baseline HbA1c and IAH and simultaneous change in HbA1c in multiple regression analyses.

Results: Respondents were predominantly male (57.5%) and non-Hispanic white (67.8%). Significant improvement over the trial was observed in hypoglycemic fear (P = .031), hypoglycemic confidence (P < .001), diabetes distress (P < .001), and device-related emotional burden (P < .001). Impaired hypoglycemic awareness at baseline predicted greater improvement in hypoglycemic fear (P = .002), hypoglycemic confidence (P = .003), diabetes distress (P = .013), and device-related emotional burden (P < .001). Higher baseline HbA1c was linked with greater improvement in hypoglycemic fear (P = .030); HbA1c change over the trial was positively associated with change in diabetes distress (P = .010) and device-related emotional burden (P = .003).

Conclusions: Introduction of rtCGM in adults with insulin-using T2D was associated with significant improvements in diabetes-related psychosocial outcomes over six months. Gains were significantly greater among participants reporting IAH and those with higher HbA1c at baseline, thus providing the first evidence regarding which users might more likely benefit.

Source: https://pubmed.ncbi.nlm.nih.gov/35533137/

Share the Post:

BDI Monthly Events

May 7OMEGA Conference
May 7: As a keynote speaker at OMEGA, the First International Conference on Once-Weekly Glycated Albumin Monitoring for Diabetes, Dr. Polonsky (BDI President) will be presenting on “Glucose Monitoring and Behavior Change” (Tokyo, Japan).
May 14Case Consultation
May 14: BDI hosts the San Diego-wide, monthly case consultation meeting (for mental health professionals working in the field of diabetes). Contact us at [email protected] if you are in the greater San Diego area and would like further information about this program.
May 18T1D Meet Up
May 18: Time for another T1D meet-up! Our friends and colleagues at GrownupT1Ds, a wonderful nonprofit here in southern California, is organizing another fun social event for adults with type 1 diabetes. This time it is a Walk, Talk & Picnic, and it begins at 11 am at the Bommer Canyon Trail (1 Sunnyhill, Irvine, CA). 92084. This event is free, but please RSVP Kelly Daes at www.grownupt1ds.org.
May 23SITEC 2025
May 23: Dr. Polonsky will be presenting (virtually) on “Far Beyond Time in Range: Exploring the Promises and Limitations of CGM” at SITEC 2025, Innovation and Technology Transforming Diabetes Care (Sao Paolo, Brazil). https://sitec.diabetes.org.br/